Effectiveness of interferon alfa‐2b/ribavirin combination therapy for chronic hepatitis C in a clinic setting

This publication has 23 references indexed in Scilit:

• A Randomized 4–Arm Multicenter Study of Interferon Alfa-2B Plus Ribavirin in the Treatment of Patients With Chronic Hepatitis C Not Responding to Interferon Alone
  Hepatology, 2001
• Combination of interferon and ribavirin in chronic hepatitis C: Re-treatment of nonresponders to interferon
  Hepatology, 2001
• Recovery, Persistence, and Sequelae in Hepatitis C Virus Infection: A Perspective on Long-Term Outcome
  Seminars in Liver Disease, 2000
• Retreatment for 24 vs 48 weeks with interferon‐α2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone
  Journal of Viral Hepatitis, 2000
• Consensus statements on the prevention and management of hepatitis B and hepatitis C in the Asia–Pacific region ¹
  Journal of Gastroenterology and Hepatology, 2000
• Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C
  New England Journal of Medicine, 1998
• Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis C
  New England Journal of Medicine, 1998
• Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
  Published by Elsevier ,1998
• French consensus conference on hepatitis C: screening and treatment
  Gut, 1998
• Meta–Analysis of Interferon Randomized Trials in the Treatment of Viral Hepatitis C: Effects of Dose and Duration
  Hepatology, 1996